Potential of Magnetic Resonance Morphometry and Laboratory Biomarkers in Investigations of the Progression of Multiple Sclerosis

被引：0

作者：

V. A. Malko ^{[1
]}

E. A. Sadovnichuk ^{[1
]}

A. S. Lepekhina ^{[1
]}

G. N. Bisaga ^{[1
]}

M. P. Topuzova ^{[1
]}

T. V. Shchukina ^{[1
]}

N. V. Dryagina ^{[1
]}

A. Yu. Efimtsev ^{[1
]}

T. M. Alekseeva ^{[1
]}

机构：

[1] Almazov National Medical Research Center, Russian Ministry of Health, St. Petersburg

来源：

Neuroscience and Behavioral Physiology | 2025年 / 55卷 / 1期

关键词：

cerebral atrophy; disease progression; glial fibrillary acidic protein; MRIM morphometry; multiple sclerosis; neurofilament light chains; phosphorylated neurofilament heavy chains;

D O I：

10.1007/s11055-025-01762-7

中图分类号：

学科分类号：

摘要：

Objective. To show that MRI morphometry (MRIM) and laboratory biomarkers are promising methods for early detection of progressive forms of multiple sclerosis (PMS). Materials and methods. A total of 81 patients with MS were examined; all underwent MRI morphology (MRIM); serum levels of neurofilament light chains (sNFL), phosphorylated neurofilament heavy chains (spNFH), and acidic glial fibrillary protein (sGFAP) were estimated by enzyme immunoassay in 60 patients. Results. Negative correlations were found between the volumes of certain brain structures and disease duration, EDSS scores, the 25-foot walking test, and the nine-peg test; positive correlations were found with performance on the symbol-digit modalities test and the Montreal Cognitive Assessment Scale. Patients with MS had smaller volumes of cerebral gray matter, cerebellar white matter, the occipital lobes, caudate nucleus, hippocampus, globus pallidus, thalamus, and nucleus accumbens. Cerebrospinal fluid (CSF) volume greater than 15.06% predicted progression of MS with a sensitivity of 77.78% and a specificity of 70.18% (CI 54.79–91%). Patients receiving MS disease-modifying drugs had larger thalamic volumes (Me 1.09% [1.06; 1.16] vs. 1.04% [0.95; 1.14]; p = 0.02) and smaller CSF volumes (13.86 ± 2.87% vs. 15.55 ± 3.49%; p = 0.03). sNFL and spNFH levels did not increase in PMS or during exacerbations, while low sNFL levels indicated that the method has low sensitivity. There were trends (p = 0.374) towards increased sGFAP in patients with PMS (Me 3.2 ng/ml [1.85; 4.6]) as compared with relapsing-remitting MS (2.05 [1.29; 4.52] ng/ml). Conclusions. The results obtained point to differences in the volumes of brain damage in patients with different types of MS and emphasize the importance of long-term follow-up for more accurate assessment of disease progression. © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2025.

引用

页码：127 / 132

页数：5

共 19 条

[1]

Correale J., Marrodan M., Ysrraelit M.C., Mechanisms of neurodegeneration and axonal dysfunction in progressive multiple sclerosis, Biomedicines, 7, 1, (2019)

[2]

Gresle M.M., Liu Y., Dagley L.F., Et al., Serum phosphorylated neurofilament-heavy chain levels in multiple sclerosis patients, J Neurol. Neurosurg. Psychiatry, 85, 11, pp. 1209-1213, (2014)

[3]

Varhaug K.N., Barro C., Bjornevik K., Et al., Neurofilament light chain predicts disease activity in relapsing-remitting MS, Neurol. Neuroimmunol. Neuroinflamm., 5, 1, (2017)

[4]

Giovannoni G., Peripheral blood neurofilament light chain levels: the neurologist’s C-reactive protein?, Brain, 141, 8, pp. 2235-2237, (2018)

[5]

Niiranen M., Kontkanen A., Jaaskelainen O., Et al., Serum GFAP and NfL levels in benign relapsing-remitting multiple sclerosis, Mult. Scler. Relat. Disord, 56, (2021)

[6]

Barro C., Healy B.C., Liu Y., Et al., Serum GFAP and NfL levels differentiate subsequent progression and disease activity in patients with progressive multiple sclerosis, Neurol. Neuroimmunol. Neuroinflamm, 10, 1, (2022)

[7]

Fisher E., Rudick R.A., Simon J.H., Et al., Eight-year follow-up study of brain atrophy in patients with MS, Neurology, 59, 9, pp. 1412-1420, (2002)

[8]

Popescu V., Agosta F., Hulst H.E., Et al., Brain atrophy and lesion load predict long term disability in multiple sclerosis, J Neurol. Neurosurg. Psychiatry, 84, pp. 1082-1091, (2013)

[9]

Paul F., Pathology and MRI: Exploring cognitive impairment in MS, Acta Neurol. Scand, 134, pp. 24-33, (2016)

[10]

Rocca M.A., Mesaros S., Pagani E., Et al., Thalamic damage and long-term progression of disability in multiple sclerosis, Radiology, 257, pp. 463-469, (2010)

← 1 2 →